Get our introductory offer at only
*$0.99/month for first 3 months
$29.90/month for the next 9 months
JOHNSON & JOHNSON agreed to buy Actelion Ltd for US$30 billion and spin off the Swiss drugmaker's research and development operations, clinching its largest deal ever to become a leader in medicines treating a rare type of high blood pressure.
With the purchase, J&...